Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity

Area of Science:

• Epigenetics
• Pharmacology

Background:

• Histone deacetylase inhibitors (HDACi) modulate gene expression through epigenetic mechanisms.
• HDACi exhibit antiproliferative, antioxidant, antineoplastic, proapoptotic, antithrombotic, and antifibrotic effects.
• Valproic acid, an established HDACi, is used for epilepsy, bipolar disorder, and migraine.

Purpose of the Study:

• To review the multifaceted therapeutic effects of HDACi.
• To explore potential new indications for HDACi based on their pleiotropic epigenetic actions.
• To highlight the need for clinical validation of HDACi for novel applications.

Main Methods:

• Literature review of existing evidence on HDACi.
• Analysis of the epigenetic mechanisms underlying HDACi effects.
• Identification of potential therapeutic targets and conditions for HDACi repurposing.

Main Results:

• HDACi demonstrate a wide range of biological activities impacting cell proliferation, apoptosis, thrombosis, and fibrosis.
• Valproic acid serves as a precedent for repurposing HDACi for conditions beyond their initial indications.
• Accumulating evidence supports exploring HDACi for cardiovascular diseases, neurodegenerative disorders, autoimmune conditions, and cancer adjuvant therapy.

Conclusions:

• HDACi possess significant therapeutic potential due to their broad epigenetic regulatory functions.
• Further research and robust clinical trials are essential to establish the safety and efficacy of HDACi for new medical conditions.
• Clinical repurposing of HDACi holds promise for treating a diverse spectrum of diseases.